We often speak about IBD as a single condition, but in reality it’s an umbrella term for distinct subtypes—most notably Ulcerative Colitis and Crohn’s Disease. While Ulcerative Colitis primarily affects the large intestine and rectum, Crohn’s Disease can appear anywhere along the gastrointestinal tract, most commonly in the terminal ileum and/or the colon. These distinctions are more than academic: they shape how doctors diagnose, treat, and manage each condition.
Ulcerative Colitis is comparatively well studied, with thousands of clinical investigations into therapies and interventions. Crohn’s Disease, however, remains more complex and less predictable—making new therapeutic insights particularly significant.
Now, a first-of-its-kind study has shed light on a novel approach: CurQD®, a proprietary combination of curcumin and Qing Dai developed by Evinature. In this clinical trial, patients with mild-to-moderate Crohn’s Disease received CurQD® during an 8–12 week induction period. Symptoms and biomarkers were closely monitored, and the results were striking: CurQD® successfully induced both clinical and biomarker remission, even among patients with prior biologic treatment experience.
The findings suggest a promising new pathway for Crohn’s patients—either as a supplement to existing therapies or as a stand-alone, gut-targeted protocol. While additional research is needed to explore the full spectrum of Crohn’s subtypes, this study provides welcome news for patients and clinicians seeking more effective, accessible options.
“This research represents an important step forward for Crohn’s patients who too often face limited or diminishing options,” says Aaron Blocker, IBD Patient Advocate (@aaronblocker_).
The study has already gained international recognition, being presented at major medical conferences including ECCO and Digestive Disease Week (DDW) 2025—two of the most influential global gatherings for gastroenterology, biotechnology, and patient advocacy.
At Evinature, we remain committed to advancing science-backed nutraceuticals designed to support patients with personalized, gut-targeted care. Explore our nutraceuticals here, or take our free online gut health assessment to see which Evinature protocol are right for you.
References:
Summer Pitocchelli-Schwartzman
